T. Takenaka

发表

Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice

S. Narimatsu, N. Hanioka, J. Kuze, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

F. Nakagawa, Y. Komiya, N. Fujita, 2019, Molecular Cancer Therapeutics.

cDNA cloning and expression of a novel type protease inhibitor (FPI-F) from the silkworm, Bombyx mori

T. Ashikari, M. Itoh, T. Takenaka, 1996 .

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114

I. Ieiri, T. Takenaka, K. Yoshisue, 2021, CPT: pharmacometrics & systems pharmacology.

Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.

M. Oshimura, Y. Kazuki, S. Abe, 2017, Drug metabolism and pharmacokinetics.

Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.

H. Akaza, T. Takenaka, T. Takenaka, 1997, European urology.

Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.

A. Kitabatake, H. Okamoto, H. Tsutsui, 2007, Biological & pharmaceutical bulletin.

Application of a Human Intestinal Epithelial Cell Monolayer to the Prediction of Oral Drug Absorption in Humans as a Superior Alternative to the Caco-2 Cell Monolayer.

T. Matsunaga, M. Chiba, J. Kuze, 2016, Journal of pharmaceutical sciences.

Human Small Intestinal Epithelial Cells Differentiated from Adult Intestinal Stem Cells as a Novel System for Predicting Oral Drug Absorption in Humans

T. Matsunaga, M. Chiba, J. Kuze, 2014, Drug Metabolism and Disposition.

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

Masanori Kato, Kimihiro Ito, K. Nishio, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Novel VEGF Receptor / MET – Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Pro fi le

Masanori Kato, Kimihiro Ito, S. Ito, 2013 .

Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.

T. Takenaka, K. Ueno, Y. Takekuma, 2007, Biological & pharmaceutical bulletin.

A Drug‐Drug Interaction Study to Evaluate the Effect of TAS‐303 on CYP3A Activity in the Small Intestine and Liver

T. Fujita, Y. Kumagai, T. Takenaka, 2020, Journal of clinical pharmacology.

Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.

A. Kitabatake, H. Okamoto, H. Tsutsui, 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam

S. Narimatsu, N. Hanioka, J. Kuze, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

Masanori Kato, Kimihiro Ito, K. Nishio, 2013, Molecular Cancer Therapeutics.

Human Small Intestinal Epithelial Cells Differentiated from Adult Intestinal Stem Cells as a Novel System for Predicting Oral Drug Absorption in Humans

T. Matsunaga, M. Chiba, J. Kuze, 2014, Drug Metabolism and Disposition.